Ultravist to enter the US market
This article was originally published in Clinica
Berlex Laboratories (US) has received US FDA clearance to market its non-ionic X-ray contrast agent, Ultravist in the US. The agent will be available in July. Ultravist injection is cleared for a range of procedures including cerebral and peripheral arteriography, excretory urography, aortography and visceral angiography, intra-arterial digital subtraction angiography, peripheral venography and CT of the head and body.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.